DRAGARWQ vs NOVARTIND: Stock Comparison
NOVARTIS INDIA is the larger company by market capitalisation. DR. AGARWAL'S EYE HOSP L shows a lower P/E, a higher ROE and a higher dividend yield, while NOVARTIS INDIA shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
DRAGARWQ leads 8; NOVARTIND leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| Live Price | ₹5,077.5 | ₹1,921.6 |
| Day Change | 0.01% | 1.26% |
| Volume | 1,328 | 12,000 |
| 52-Week High | ₹6,059.7 | ₹2,588.8 |
| 52-Week Low | ₹4,600 | ₹950 |
| Distance from 52W High | -16.21% | -25.77% |
Valuation
| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| Market Cap | ₹2,455 Cr | ₹4,753 Cr |
| P/E Ratio | 32.2x | 48.61x |
| P/B Ratio | 7.09x | 5.81x |
| EPS | ₹48.38 | ₹13.05 |
| Book Value | ₹716.56 | ₹331.23 |
| Dividend Yield | 0.14% | 0% |
Growth
| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 8% |
| EPS Growth (TTM YoY) | 0% | -13.8% |
| Qtr Sales Growth | 19.13% | 14.64% |
| Qtr Profit Growth | 43.97% | 27.56% |
Profitability & Leverage
| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| ROE | 20.24% | 11.39% |
| ROCE | 18.74% | 14.33% |
| Net Margin | 14.89% | 26.3% |
| Operating Margin | 22.4% | 36.95% |
| Debt to Equity | 0.24x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | DRAGARWQ | NOVARTIND |
|---|---|---|
| Promoter Holding | 72.67% | 0% |
| FII Holding | 2.24%▲ 0.04 pp | 0.16%▼ 0.01 pp |
| DII Holding | 2.05%▼ 0.07 pp | 1.36%▲ 0.83 pp |
| Public Holding | 23.04%▲ 0.04 pp | 27.8%▼ 0.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. AGARWAL'S EYE HOSP L and NOVARTIS INDIA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.